Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
, 84 (12), 2704-2715

The Impact of CYP2D6 Mediated Drug-Drug Interaction: A Systematic Review on a Combination of Metoprolol and Paroxetine/Fluoxetine

Affiliations
Case Reports

The Impact of CYP2D6 Mediated Drug-Drug Interaction: A Systematic Review on a Combination of Metoprolol and Paroxetine/Fluoxetine

Muh Akbar Bahar et al. Br J Clin Pharmacol.

Abstract

Aim: Metoprolol (a CYP2D6 substrate) is often co-prescribed with paroxetine/fluoxetine (a CYP2D6 inhibitor) because the clinical relevance of this drug-drug interaction (DDI) is still unclear. This review aimed to systematically evaluate the available evidence and quantify the clinical impact of the DDI.

Method: Pubmed, Web of Science, Cochrane Library and Embase were searched for studies reporting on the effect of the DDI among adults published until April 2018. Data on pharmacokinetics, pharmacodynamics and clinical outcomes from experimental, observational and case report studies were retrieved. The protocol of this study was registered in PROSPERO (CRD42018093087).

Results: We found nine eligible articles that consisted of four experimental and two observational studies as well as three case reports. Experimental studies reported that paroxetine increased the AUC of metoprolol three to five times, and significantly decreased systolic blood pressure and heart rate of patients. Case reports concerned bradycardia and atrioventricular block due to the DDI. Results from observational studies were conflicting. A cohort study indicated that the DDI was significantly associated with the incidence of early discontinuation of metoprolol as an indicator of the emergence of metoprolol-related side effects. In a case-control study, the DDI was not significantly associated with bradycardia.

Conclusion: Despite the contradictory conclusions from the current literature, the majority of studies suggest that the DDI can lead to adverse clinical consequences. Since alternative antidepressants and beta-blockers with comparable efficacy are available, such DDIs can be avoided. Nonetheless, if prescribing the combination is unavoidable, a dose adjustment or close monitoring of the metoprolol-related side effects is necessary.

Keywords: CYP2D6; drug-drug interaction; metoprolol; paroxetine/fluoxetine.

Figures

Figure 1
Figure 1
Flow diagram literature search and screening process

Similar articles

See all similar articles

References

    1. Joynt KE, Whellan DJ, O'Connor CM. Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry 2003; 54: 248–261. - PubMed
    1. Garcia Vicente E, Del Villar Sordo V, Garcia Y, Garcia EL. Post‐myocardial infarction depression. An Med Interna 2007; 24: 346–351. - PubMed
    1. Strik JJ, Honig A, Maes M. Depression and myocardial infarction: relationship between heart and mind. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 879–892. - PubMed
    1. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, et al Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104: 2024–2028. - PubMed
    1. Herlitz J, Wikstrand J, Denny M, Fenster P, Heywood T, Masszi G, et al Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. J Card Fail 2002; 8: 8–14. - PubMed

Publication types

Feedback